Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPEPPS | P55786 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CCNE2 | O96020 | 5/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.36 |
| ▸ | CDK2 | P24941 | 5/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 2/20 | 0.35 |
| ▸ | CCND1 | P24385 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 2/20 | 0.34 |
| ▸ | DDO | Q99489 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25532959 | 0.82 | KRAS (0.39) | HTTALDH1A1 | |
| SCHEMBL21543080 | 0.82 | NPEPPS (0.47) | NPEPPSPOLBHTTALDH1A1KDM4E | |
| SCHEMBL30586683 | 0.82 | NPEPPS (0.47) | NPEPPSPOLBHTTALDH1A1KDM4E | |
| SCHEMBL20560356 | 0.82 | CCNE2 (0.37) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL21543391 | 0.82 | MAPK13 (0.43) | NPEPPSHTTALDH1A1KDM4ELMNA | |
| SCHEMBL30762745 | 0.82 | MAPK13 (0.43) | NPEPPSHTTALDH1A1KDM4ELMNA | |
| SCHEMBL20560354 | 0.80 | CCNE2 (0.36) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL23234780 | 0.79 | KRAS (0.36) | HTTALDH1A1PDE9A | |
| SCHEMBL30762757 | 0.78 | MAPK13 (0.39) | ALDH1A1LMNATNKS2PARP1 | |
| SCHEMBL20560733 | 0.78 | MAPK13 (0.39) | ALDH1A1LMNATNKS2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230159529-A1 | AROMATIC COMPOUND AND APPLICATION THEREOF IN ANTITUMOR DRUG | SHANGHAI ZHEYE BIOTECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159529-A1 | AROMATIC COMPOUND AND APPLICATION THEREOF IN ANTITUMOR DRUG | SHANGHAI ZHEYE BIOTECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-08-17 | — | — | US | disclosed |
| EP-3788038-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | NPEPPS 3126/4885POLB 549/4885HTT 2514/4885 |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | NPEPPS 3126/4885POLB 549/4885HTT 2514/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | NPEPPS 3126/4885POLB 549/4885HTT 2514/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | NPEPPS 3126/4885POLB 549/4885HTT 2514/4885 |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | NPEPPS 3126/4885POLB 549/4885HTT 2514/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | NPEPPS 3126/4885POLB 549/4885HTT 2514/4885 |
| US-20230159529-A1 | AROMATIC COMPOUND AND APPLICATION THEREOF IN ANTITUMOR DRUG | TYR, APC, TP53 | NPEPPS 165/4885POLB 4308/4885HTT 2198/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | NPEPPS 3126/4885POLB 549/4885HTT 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.